Omigapil (free base)

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 412649

CAS#: 181296-84-4 (free base)

Description: Omigapil (free base) is a drug that was developed by Novartis and tested in clinical trials for its ability to help treat Parkinson's disease and amyotrophic lateral sclerosis

Chemical Structure

img
Omigapil (free base)
CAS# 181296-84-4 (free base)
Instruction

Theoretical Analysis

MedKoo Cat#: 412649
Name: Omigapil (free base)
CAS#: 181296-84-4 (free base)
Chemical Formula: C19H17NO
Exact Mass: 275.13
Molecular Weight: 275.350
Elemental Analysis: C, 82.88; H, 6.22; N, 5.09; O, 5.81

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 181296-84-4 (free base)   200189-97-5 (maleate)    

Synonym: Omigapil (free base); CGP3466; CGP-3466; CGP 3466

IUPAC/Chemical Name: N-(dibenzo[b,f]oxepin-10-ylmethyl)-N-methylprop-2-yn-1-amine

InChi Key: QLMMOGWZCFQAPU-UHFFFAOYSA-N

InChi Code: InChI=1S/C19H17NO/c1-3-12-20(2)14-16-13-15-8-4-6-10-18(15)21-19-11-7-5-9-17(16)19/h1,4-11,13H,12,14H2,2H3

SMILES Code: CN(CC1=Cc2c(Oc3c1cccc3)cccc2)CC#C

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 275.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Yu Q, Sali A, Van der Meulen J, Creeden BK, Gordish-Dressman H, Rutkowski A, Rayavarapu S, Uaesoontrachoon K, Huynh T, Nagaraju K, Spurney CF. Omigapil treatment decreases fibrosis and improves respiratory rate in dy(2J) mouse model of congenital muscular dystrophy. PLoS One. 2013 Jun 6;8(6):e65468. doi: 10.1371/journal.pone.0065468. PMID: 23762378; PMCID: PMC3675144.

2: Gale TV, Horton TM, Hoffmann AR, Branco LM, Garry RF. Host Proteins Identified in Extracellular Viral Particles as Targets for Broad-Spectrum Antiviral Inhibitors. J Proteome Res. 2019 Jan 4;18(1):7-17. doi: 10.1021/acs.jproteome.8b00204. Epub 2018 Nov 5. PMID: 30351952.

3: Sen T, Saha P, Sen N. Nitrosylation of GAPDH augments pathological tau acetylation upon exposure to amyloid-β. Sci Signal. 2018 Mar 20;11(522):eaao6765. doi: 10.1126/scisignal.aao6765. PMID: 29559585; PMCID: PMC6371980.

4: Erb M, Meinen S, Barzaghi P, Sumanovski LT, Courdier-Früh I, Rüegg MA, Meier T. Omigapil ameliorates the pathology of muscle dystrophy caused by laminin- alpha2 deficiency. J Pharmacol Exp Ther. 2009 Dec;331(3):787-95. doi: 10.1124/jpet.109.160754. Epub 2009 Sep 16. PMID: 19759319.

5: Meinen S, Lin S, Thurnherr R, Erb M, Meier T, Rüegg MA. Apoptosis inhibitors and mini-agrin have additive benefits in congenital muscular dystrophy mice. EMBO Mol Med. 2011 Aug;3(8):465-79. doi: 10.1002/emmm.201100151. Epub 2011 Jun 15. PMID: 21674808; PMCID: PMC3377088.

6: Sarkozy A, Foley AR, Zambon AA, Bönnemann CG, Muntoni F. LAMA2-Related Dystrophies: Clinical Phenotypes, Disease Biomarkers, and Clinical Trial Readiness. Front Mol Neurosci. 2020 Aug 5;13:123. doi: 10.3389/fnmol.2020.00123. PMID: 32848593; PMCID: PMC7419697.

7: Harraz MM, Snyder SH. Nitric Oxide-GAPDH Transcriptional Signaling Mediates Behavioral Actions of Cocaine. CNS Neurol Disord Drug Targets. 2015;14(6):757-63. doi: 10.2174/1871527314666150529150143. PMID: 26022259; PMCID: PMC4831565.

8: Yacoubian TA, Standaert DG. Targets for neuroprotection in Parkinson's disease. Biochim Biophys Acta. 2009 Jul;1792(7):676-87. doi: 10.1016/j.bbadis.2008.09.009. Epub 2008 Oct 1. PMID: 18930814; PMCID: PMC2740981.

9: LeWitt PA. Clinical trials of neuroprotection for Parkinson's disease. Neurology. 2004 Oct 12;63(7 Suppl 2):S23-31. doi: 10.1212/wnl.63.7_suppl_2.s23. PMID: 15477583.

10: Snider NT, Portney DA, Willcockson HH, Maitra D, Martin HC, Greenson JK, Omary MB. Ethanol and Acetaminophen Synergistically Induce Hepatic Aggregation and TCH346-Insensitive Nuclear Translocation of GAPDH. PLoS One. 2016 Aug 11;11(8):e0160982. doi: 10.1371/journal.pone.0160982. PMID: 27513663; PMCID: PMC4981434.